REDWOOD CITY, Calif.,
Nov. 5, 2015 /PRNewswire/
-- Cardica, Inc. (Nasdaq: CRDC) today announced that
Thomas J. Palermo will join the
company November 16 as chief
operating officer, responsible for all aspects of research and
development, operations and regulatory affairs, reporting to
Julian Nikolchev, president and CEO
of Cardica..
"Over the course of the last nine months, Tom has directed the
changes to the MicroCutter XCHANGE® 30 device as a
consultant, and we are extremely pleased to welcome him to the
executive team," said Julian
Nikolchev, president and CEO of Cardica. "Tom brings great
value to the team, demonstrated by the significant improvements in
reliability and performance of the MicroCutter XCHANGE®
30 system under his leadership. We believe he will be instrumental
in the continued advancement of the company in terms of product
development and operational efficiency."
Mr. Palermo brings close to 30 years of medical device
development and management expertise to Cardica. Most recently, he
served as acting CEO of UlceRx Medical, a start-up chronic wound
care company. Prior to UlceRx, Mr. Palermo was president and CEO of
ReVascular Therapeutics (acquired by Boston Scientific in 2011),
where he revamped the technology platform to meet the market demand
for the TruePath CTO Device system. Prior to ReVascular
Therapeutics, he served as vice president of operations and
engineering at Ensure Medical where he was responsible for
regulatory, clinical, quality assurance, research and development
and operations for the development of ExoSeal bio-absorbable
femoral closure device. Prior to Ensure Medical, he served in a
variety of escalating roles related to engineering, operations,
research and development and business development at a variety of
medical device companies. He received his B.S. degree in Technical
Management from New Hampshire College
and holds more than 40 issued and pending patents.
About Cardica
Cardica designs and manufactures proprietary stapling and
anastomotic devices for cardiac and laparoscopic surgical
procedures. Cardica's technology portfolio is intended to
reduce operating time and facilitate minimally-invasive and
robot-assisted surgeries. Cardica's MicroCutter XCHANGE®
30, a cartridge-based articulating surgical stapling device with a
five-millimeter shaft diameter, is manufactured and cleared for use
in a variety of gastrointestinal procedures and appendectomies in
the United States, and for a wide
range of surgical procedures in Europe. In addition, Cardica manufactures and
markets its automated anastomosis systems, the C-Port®
Distal Anastomosis Systems and PAS-Port® Proximal
Anastomosis System for coronary artery bypass graft (CABG) surgery,
and has shipped over 56,500 units throughout the world.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cardica-appoints-thomas-j-palermo-as-chief-operating-officer-300173520.html
SOURCE Cardica, Inc.